

L4.



maco

Team 44



إذا اختلّ الرذم لا تنسى أربع تسكّرها وتعالج فيها بايدك غير الصوديوم بيتا وترى اسمع كالسيوم، بوتاسيوم تفيدك 羔 على العبدالعظيم





Understand definition of arrhythmias & their different types.



Describe different classes of Antiarrhythmic drugs & their mechanism of action.



Understand their pharmacological actions, clinical uses, adverse effects & their interactions with other drugs.







### Ventricular Muscle Cell Action Potential Phases:

(Resting membrane potential): Polarized

Influx of Na+ and Ca++ from neighboring cardiac cells causes the resting membrane potential to slightly increase, allowing voltage gated Na channels to open, and the cell is said to be depolarized.

At peak positivity of the cell, short-term voltage-gated K+ channels open and Na+ channels close. This allows the membrane potential to be slightly decreased to create a potential difference for voltage gated Ca++ channels to open.

Voltage gated Ca++channels are open for about most of the period, but the channels are inactivated around the end of this phase and phase 3 ( K+ efflux starts). If this phase is prolonged, inactivated Ca++ channels can reopen, creating an after depolarization (torsades de pointes).

Phase 3


Phase 2

Phase 4

Phase 0

Phase 1

Extra specialized K+ channels are opened to bring about repolarization and a return to the resting membrane potential







### **Pacemaker Action Potential Phases:**

SA Node is made of specialized cardiac cells (Modified Cardiomyocytes) that exhibit a unique way of generating an action potential (automaticity; do not require CNS stimulation). These cells have high permeability to Na+ and K+, allowing constant, spontaneous action potentials to be generated

#### -What is the difference between the pacemaker and non-pacemaker AP ?

the plateau phase in the non-pacemaker AP, The pacemaker (SA node) initiates electrical impulses in the heart, regulating the rhythm and heart rate. Non-pacemaker action potentials transmit these signals throughout the heart, coordinating the contraction and relaxation of the atria and ventricles.

# Types of arrhythmia

#### Ventricular (occurs in the ventricles)

#### Supraventricular (occurs in the atria)

#### Ventricular Tachycardia:

SA node no longer controls the beating of the ventricles "ectopic pacemaker", this will result in increase heart beats Paroxysmal Supraventricular Tachycardia: Rapid, regular heart beats

#### Premature Ventricular Contractions (PVC):

the condition happens when the ventricles contract too soon, out of sequence with the normal

Wolff-Parkinson-White Syndrome: Extra electrical pathways between the atria and the ventricles,the result is a very fast heart rate

#### Ventricular Fibrillation:


The most serious arrhythmia, impulses stimulate one part of the ventricles, then another, then itself. Many parts contract at the same time while other parts relax (Circus movement)


## Atrial Fibrillation: Rapid, irregular heart beats.

Atrial flutter: Regular, atrium beats faster than ventricle.

# **Cardiac conduction system**

The conduction system within the heart is responsible for generating and conducting impulses to all part of the heart:






### **Classification of Antiarrhythmic Drugs**

Vaughan- Williams Classification	I	п	III	IV	V
М.О.А	Na+ channel blockers (membrane stabilizing drugs). The Na+ channel is the starting of AP in both atria and ventricles	β- Adrenorecept Blockers	K+ Channel blockers	Ca++ Channel blockers	Other M.O.A
Effects on Pacemaker Action Potential	<ol> <li>1- Decrease the rate of rise of rapid depolarization (phase 0).</li> <li>2- Decrease phase 4 slow depolarization (suppress pacemaker activity).</li> </ol>	Slow Phase 4 depolarization.	Prolongs Action Potential Repolarization	Slow phase 4 → spontaneous depolarization and conduction.	-
Drugs	Ia-Quinidine & Procainamide. Ib-Lidocaine & Mexiletine. Ic-Flecainide.	1-Esmolol. 2-Propranolol. 3-Metoprolol. 4-Atenolol.	1-amiodarone 2-Ibutilide.	1-Verapamil 2-Diltiazem	Adennosine



**Class I Drugs** 





اخر ثلاثه فيها cain

#### **Class Ia**

Drug	АР	Pharmacological action	Clinical use	ADRs
Quinidine Orally (Rarely I.V)	Important Prolong the action potential duration	<ol> <li>Anticholinergic effects         <ul> <li>(Atropine like effect):</li></ul></li></ol>	1- Atrial flutter & fibrillation. (both are tachycardia, but the difference is : the flutter is regular rapid heart rate, while the fibrillation is irregular rapid heart rate) 2- Maintaining sinus rhythm after cardioversion ( electrical supply of the heart) 3-we can use it in malaria	<ol> <li>Quinidine syncope: episodes of fainting due to torsades de pointes (twisting of the spikes) developing at therapeutic plasma levels. <i>providential</i> <i>international</i> 2. Anticholinergic adverse effects: Dry mouth, blurred vision, urinary retention constipation.</li> <li>Hypotension: Due to depressing contractility &amp; vasodilation.</li> </ol>
Procainamide I.V		Similar to Quinidine except: 1. Less toxic on the heart (can be given I.V). 2. More effective in ventricular than in atrial arrhythmia. 3. Less anticholinergic or a- blocking actions.	More effective in Ventricular than atrial arrhythmia.	<ol> <li>Torsades de pointes (at toxic dose).</li> <li>In long term therapy, it causes <u>reversible</u> lupus erythematosus like syndrome.</li> <li>Hypotension -&gt; Because it reduces peripheral resistance.</li> <li>Hallucination &amp; psychosis.</li> </ol>

Torsades de pointes: may terminate spontaneously or lead to fatal ventricular fibrillation




## class Ib

Drug	АР	Administration	Clinical use	ARDs
Lidocaine (T ½ : 2H) is a widely used local anesthetic that is commonly used in dentistry.	Shorten the Action potential duration	Given I.V. bolus or slow infusion. - <b>Not effective orally</b> (low bioavailability [3%] due to first pass metabolism) t1/2 = 2 h	Treatment of emergency ventricular arrhythmias: 1- during surgery. 2-following acute myocardial infarction. Not effective in atrial arrhythmias	1- Hypotension 2- CNS ADRs (similar to other local anesthetics), in order : -Paresthesia( numbness) -Tremor -Dysarthria (slurred speech) -Tinnitus -Confusion -Convulsion
Mexiletine (T ½ : 10H)		<b>Effective orally</b> t1/2 = 10 h	1- Ventricular arrhythmias. 2- Digitalis induced arrhythmias (digoxin induced arrhythmias)	<ol> <li>1- Nausea, vomiting</li> <li>2- tremor, drowsiness,</li> <li>diplopia(double vision).</li> <li>3- arrhythmias &amp; hypotension.</li> </ol>

#### class Ic

Drug	АР	Clinical use	ARDs
Flecainide	No effect on action potential duration. (Markedly slow phase 0 depolarization) "very potent and pure Na channel blockers"	<ol> <li>Supraventricular arrhythmias</li> <li>Should be reserved for resistant arrhythmias.</li> <li>Very effective in ventricular arrhythmias, but very high risk of <b>proarrhythmia</b>.</li> <li>Wolff Parkinson White syndrome.</li> </ol>	<ol> <li>Proarrhythmia. (Cause new arrhythmia)</li> <li>CNS : dizziness , tremor, blurred vision, abnormal taste sensations, paraesthesia.</li> <li>Heart failure due to (-ve) inotropic effect.</li> </ol>

Is Pre-excitation of the ventricles due to an **accessory pathway** known as the Bundle of Kent.





## Class II drugs

drug	<b>Esm<u>olol</u></b> (T 1/2 : 9min)	Propran <u>olol,</u> Aten <u>olol</u> & Metopr <u>olol</u>
<i>Important</i> M.O.A / Pharmacological action	<ul> <li>β-AdrenoreceptBlockers</li> <li>Block B1 receptors in the heart reducing sympathetic effect on the heart which leads to:</li> <li>1- Decrease automaticity of S.A node &amp; ectopic pacemakers.</li> <li>2- Prolong refractory period (slow conduction) of the A.V node.</li> </ul>	
Clinical uses / therapeutic uses	<ol> <li>Atrial arrhythmias associated with emotions         <ul> <li>(e.g: after exercise, thyrotoxicosis). We can use it as protective.</li> <li>Wolff Parkinson White syndrome. (WPW)</li> </ul> </li> <li>Digitalis induced arrhythmias (digoxin induced arrhythmias).</li> </ol>	
Specific uses	<ul> <li>Very short acting (half-life =9min)</li> <li>Given I.V. for rapid control of ventricular rate in patients with atrial flutter or fibrillation.</li> </ul>	• Used in patients <u>who had</u> <u>myocardial infarction</u> to reduce incidence of sudden death due to ventricular arrhythmias. (prophylaxis)



## **Class III drugs**

Drug	أم يدرون <b>1- Amiodarone</b>	
Pharmacological action	Mainly cause: 1- Prolong AP duration and prolong refractory period. (Main effect) 2- Prolong phase 3 repolarization. And additional effects: يسوي Block يسوي • Class IA (Membrane stability + a-adrenergic blocking effect). • Class II (B1 Blocker). • Class IV (Ca Block). • Vasodilating effects (due to its alpha & 3-adrenoceptor blocking effects and its calcium channel blocking effects).	
<i>Important</i> Pharmacokinetic	<ul> <li>Extremely long half-life (13 - 103 Days).</li> <li>Metabolized by (CYP3A4 and CYP2C8) to its major active metabolite: N-desethylamiodarone.</li> <li>Eliminated primarily by hepatic metabolism (so it's contraindicated in patients with liver problems).</li> <li>Can cross placenta, and appear in breast milk (so it's contraindicated in pregnant woman and breastfeeding).</li> </ul>	
Clinical uses / therapeutic uses	<ol> <li>Main use: serious resistant ventricular arrhythmias.</li> <li>Maintenance of sinus rhythm after D.C. cardioversion.</li> <li>Resistant supraventricular arrhythmias e.g. WPW.</li> </ol>	
<i>Important</i> ADRs	<ul> <li>Exacerbation of ventricular arrhythmias (high dose).</li> <li>Bradycardia and heart failure.</li> <li>Pulmonary fibrosis &amp; necrosis.</li> <li>Hyper or hypothyroidism (because it contain iodine). *contraindicated in thyrotoxicosis</li> <li>Photodermatitis &amp; skin deposits ( patients should avoid exposure to the sun).</li> <li>Neurological (e.g. tremors and peripheral neuropathy).</li> <li>Nausea, vomiting and constipation.</li> <li>Corneal micro deposits.</li> <li>Hepatocellular necrosis.</li> </ul>	

Drug interactions	<ul> <li>1-Co-administration of amiodarone with drugs that prolong the QT interval increases the risk of Torsades de Pointes. (e.g&gt; Macrolides antibodies: Clarithromycin &amp; Erythromycin&gt; Azole antifungals : Ketoconazole).</li> <li>2- Drugs (or substances) that inhibit CYP3A4 &amp; CYP2C8 enzymes cause increase in serum concentration of amiodarone. (e.g. Loratadine, Ritonavir (AIDS/HIV drug), Trazodone (antidepressant), Cimetidine, Grapefruit juice).</li> <li>3- Drugs that induce these enzymes cause decrease in serum concentration of amiodarone. (e.g. Rifampin).</li> </ul>
Drug	کذب الجمال <- Beauty lied → کذب الجمال (Pure class III)
<i>Important</i> M.O.A / Pharmacological action	1-Prolong the Action potential duration & RP 2-Prolong phase 3 repolarization -Causes QT interval prolongation (phase3)
Clinical use	Used for acute conversion of atrial flutter or fibrillation to normal sinus rhythm
Administration	Given by rapid I.V infusion
<i>Important</i> ADRs	May cause Torsades De pointes



## **Class IV Drugs**

Drug	1- Verapamil 2- Diltiazem
M.O.A/ pharamcological action	<ul> <li>Calcium channel blockers (heart selective)</li> <li>Main site of action is S.A &amp; A.V nodes causes:         <ol> <li>Slowing of conduction</li> <li>Prolongation of effective refractory period (ERP)</li> </ol> </li> </ul>
Clinical use	<ol> <li>Atrial arrhythmias</li> <li>Re-entry supraventricular arrhythmias (e.g. WPW)</li> <li>NOT effective in ventricular arrhythmia (because they have action more on SA &amp; AV nodes)</li> </ol>



Drug	Adenosine (Miscellaneous Antiarrhythmic Drugs)	
М.О.А	Inhibit cAMP by binding to adenosine A1 receptors causing the following actions:         1- Opening of potassium channels (Hyperpolarization)         2-Decreasing conduction velocity ,mainly at AV node (Negative dromotropic effect) and chronotropic effect         3- Inhibiting phase 4 pacemaker action potential at SA node (Negative chronotropic effect)	
Pharmacokinetics	Half life = less than 10 sec	
Therapeutic uses	<ul> <li>Drug of choice for acute management of paroxysmal supraventricular tachycardia</li> <li>preferred over verapamil (because it's safer and does not depress contractility)</li> </ul>	
ADRs	<ol> <li>Flushing (in about 20% of patients) vasodilation of superficial vessels</li> <li>Shortness of breath &amp; chest burning (in 10% of patients) due bronchospasm</li> <li>Brief A.V block (Contraindicated in heart block)</li> </ol>	
New Antiarrhythmic Drugs		
Drug	Dronedarone	
Overview	A non-iodinated congener of Amiodarone	
Pharmacological action	It has antiarrhythmic properties belonging to all four classes	
Uses	Used for maintenance of sinus rhythm following cardioversion in patients with atrial flutter or fibrillation	
Contraindications -warning-	<ul> <li>Should NOT be used in patients with severe (class IV) heart failure. (Risk of death may be increased in these patients)</li> <li>Should NOT be used in patients with permanent atrial fibrillation. (Risk of death and stroke may be increased in these patients)</li> </ul>	


## Bradyarrhythmias

Drug	Atropine sympathomimetics
Uses	<ul> <li>Used in sinus bradycardia after myocardial infarction and in heart block</li> <li>In emergency heart block isoprenaline (non-selective beta-adrenegic agonist) may be combined with atropine (caution) due to its additive effects</li> </ul>

# Nonpharmacological Therapy of Arrhythmias

# Implantable Cardiac Defibrillator (ICD):

- Can automatically detect and treat fatal arrhythmias. such as ventricular fibrillation
- used if pharmacological options didn't work



### " study smarter , not harder "

## **Active recall**




For Anki flash cards click the icon



Take active quizzes in our team channel to test your understanding.

#### summary



Highly recommended !!




click the icon to get free flash cards








5 Which of the following drugs is used for rapid control of ventricular rate in patients with atrial flutter or fibrillation?



2)D (2) V2) C 8)B









# **Lecture Done by :**

Madaen Alarifi **Yazeed Alghazi** Nisreen Alotaibi Talal Alrobaian

# **Team Leaders :**

**Ritaj Alsubaie** Ali Al Abdulazem

Sarah Alajmy Waleed Alanazi Abdullah Balbaid

Contact us at : pharmacology.444ksu@gmail.com